INTRODUCTION: Pregnancy is associated with physiologic changes causing alterations in cardiovascular hemodynamics, sometimes result- ing heart failure (HF) symptoms which should be distinguished as physiologic or pathologic. We hypothesized that pregnant women with HF symptoms are more likely to have a difference in cardiac structure and function as determined by transthoracic echocardiogram (TTE). METHODS: 237 pregnant women with no known cardiac history underwent TTE and questionnaires in the 3rd trimester and five months postpartum. HF symptoms were classified using modified Boston criteria (MBS), National Health and Nutrition Examination Survey (NHANES), and New York Heart Association (NYHA). RESULTS: 48 patients (18%) had HF symptoms by MBS, 56 (24%) by NHANES, 148 (62%) had NYHA Class III/IV symptoms, and 24 patients (10%) met all 3 criteria. Self-reported symptoms including lack of energy, early satiety, and palpitations were correlated with higher HF scores on all scales (P CONCLUSION: The 3rd trimester brings subtle changes in cardiac structure and function that may be associated with HF symptoms. While some pregnant women meet HF criteria based on symptoms and have corresponding differences on TTE, it is reassuring that these changes resolve postpartum and likely reflect physiologic changes in pregnancy. Financial Disclosure: The authors did not report any potential conflicts of interest. Use of Intrauterine Pressure Catheters (IUPC) Increases Risk of Post-Cesarean Surgical Site Infection [9B] Kara M. Rood, MD The Ohio State University Wexner Medical Center, Columbus, OH Stephen Gee, MD, Katherine Millen, MD, Brian Kellert, DO, Catalin Buhimschi, MD, and Mark Klebanoff, MD, MPH INTRODUCTION: Surgical site infection (SSI) rates are increasingly being linked to payment incentives for hospitals and represent an important clinical quality indicator of care. Clinical interventions aimed to significantly reduce cost and morbidity can be designed through identification of key predisposing obstetrical risk factors for SSI. Studies conducted in a limited number of subjects suggest an association between IUPC and post-partum endomyometritis. Our objective was to examine the relationship between intra-partum use of IUPC and risk of post-cesarean SSI. METHODS: We performed a secondary analysis using data from Maternal-Fetal Medicine Units Network (MFMU) Cesarean Registry (1999-2002). Patients included in this analysis had a singleton viable pregnancy and a cesarean delivery following labor for recognized obstetrical indication from 24 to 42 weeks gestational age (GA). A multivariable logistic regression model was used to control for GA, race, BMI at delivery, smoking, limited prenatal care, length of labor, length of membrane rupture, PPROM, pre-gestational diabetes, hypertensive diseases, physical health status assessed using American Society of Anesthesiologists established categories, and maternal clinical chorioamnionitis. RESULTS: 25,986 women were included in this analysis. The rate of SSI was 12.9% (1,542 of 11,941) in the patients with IUPC and 7.8% (1,099 of 14,045) in the patients without IUPC (P5, 0.001). The adjusted Odds Ratio for SSI among patients who had IUPC was 1.40, (95% CI51.26-1.57, P5, 0.001). CONCLUSION: We present compelling data that in laboring women undergoing cesarean delivery, the use of IUPC is an independent risk factor for post-cesarean SSI. Financial Disclosure: The authors did not report any potential conflicts of interest. Effect of Chronic Kidney Disease Stage on Pregnancy Outcomes [10B] Karen Scrivner Oregon Health and Science University, Portland, OR Blake Zwerling, and Aaron B. Caughey, MD, PhD INTRODUCTION: This study aims to estimate the risk of adverse pregnancy outcomes in women with stages 1-5 chronic kidney disease (CKD). METHODS: This is a retrospective cohort study of 2,039,870 singleton, non-anomalous pregnancies recorded in the California Birth Registry from 2006 to 2010, of which 93 were complicated by CKD. 27 women were classified as stage 1 or 2, 21 as stage 3, 10 as stage 4 and 35 as stage 5 CKD. Outcomes included: preeclampsia, preterm delivery, intrauterine fetal demise (IUFD), small for gestational age neonates (SGA), and mode of delivery. Results were stratified by parity and analyzed with Pearson Chi-squared Tests and multivariable logistic regression analyses. RESULTS: Compared to the general population, all stages of CKD resulted in higher rates of adverse pregnancy outcomes. Women with stage 4 CKD experienced the highest rates of preeclampsia, preterm delivery, and IUFD (60.0%, 100.0%, and 10.0% respectively, all P. CONCLUSION: Although all stages of CKD are associated with worse pregnancy outcomes compared with the general population, there was a non-linear relationship between the severity of pregnancy outcomes and degree of kidney dysfunction. Those with more progressed disease on renal replacement therapy may account for the improved outcomes. Further research with a larger cohort is needed to better understand the impact of this chronic disease on pregnancy. Financial Disclosure: Aaron Caughey disclosed the following—Celmatix: Consultant/Advisory Board. The other authors did not report any potential conflicts of interest. Diagnostic Testing Uptake After High-Risk cffDNA Results for Sex Chromosome Aneuploidy [11B] Anju Suhag, MD Baylor College of Medicine, Houston, TX Patricia Robbins-Furman, MPH, CGC, Manju Monga, MD, Lisa Hollier, MD, Susan Ramin, MD, and Ignatia B. Van den Veyver, MD INTRODUCTION: The phenotype of sex chromosome aneuploidy (SCA) is typically mild, except in fetuses with cystic hygroma/hydrops. We hypothesize that because the phenotype of SCA is variable, the uptake of diagnostic testing after positive cffDNA screening varies between different SCA. Our study aim was to describe the uptake of diagnostic testing after a positive cffDNA screen for SCA. METHODS: A retrospective study of singleton gestations and abnormal cffDNA results for 45,X, 47,XXY or other SCA from 10/2012 to 3/2016. Any unreportable and other positive cffDNA results were excluded. Based on cffDNA results, 3 cohorts were defined: high-risk for 45,X, 47,XXY or other SCA. Diagnostic testing was offered to all study subjects. Primary outcome was uptake rate of diagnostic testing by abnormal cffDNA SCA results in 3 groups. P-value of , .05 was considered significant. RESULTS: 109 women met inclusion criteria. Demographics were similar in the 3 groups. The overall uptake of diagnostic testing after abnormal cffDNA for SCA was 22.9%. It was higher in 45,X cohort (36.7%) compared to 47,XXY (14.3%); none of the patients in “other SCA” cohort accepted diagnostic testing (P5.0004). The false positive and confirmation rate of suspected chromosomal abnormality was sim- ilar in 45,X and 47,XXY group (P5.68). CONCLUSION: Only 23% of women with positive cffDNA for SCA proceed with diagnostic testing. Of all SCA, the uptake is noted to be highest for 45,X. The increased uptake in 45,X may be due to a higher likelihood of abnormal ultrasound findings such as cystic hygroma. Further analysis of this observation is indicated. Financial Disclosure: The authors did not report any potential conflicts of interest. Highlights of Morcellation and Sarcoma Incidence in German Patients Admitted for Uterine Fibroid Surgery [12B] Liselotte Mettler, MD University Hospitals Schleswig-Holstein, Kiel, Germany Khulkar Abdusattarova, MD 22S SATURDAY POSTERS OBSTETRICS & GYNECOLOGY Copyright ª by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.